Allianz Asset Management
GEVA

Allianz Asset Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Allianz Asset Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-148,775
Closed -$14.5M – 2608
2015
Q1 		$14.5M Sell
148,775
-62,870
-30% -$6.66M 0.02% 800
2014
Q4 		$19.6M Buy
211,645
+80,540
+61% +$6.36M 0.02% 714
2014
Q3 		$9.02M Buy
131,105
+41,325
+46% +$2.96M 0.01% 865
2014
Q2 		$9.41M Buy
+89,780
New +$7.64M 0.01% 753

Allianz Asset Management's GEVA Position: Q2 2015 in Review

Allianz Asset Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 148,775 shares — an estimated $14.5M sold.

Allianz Asset Management first reported a position in GEVA in Q2 2014 and held it in 4 quarters. The position peaked at $19.6M in Q4 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Allianz Asset Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Allianz Asset Management sold 148,775 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $14.5M.
  • Allianz Asset Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2014 and held it in 4 quarters.
  • Allianz Asset Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $19.6M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Allianz Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.